Article
The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.
Journal of the National Cancer Institute - 1 Jan 2026
Wooster Margaux, May Michael, Agrawal Prashasti, Lee Jonathan, May Benjamin, Ma Xin, Bogdan Stephanie, Shu Catherine A, Henick Brian S, Saqi Anjali, Mansukhani Mahesh, Riely Gregory, Hershman Dawn L, Garcia Christine, Arbour Kathryn C, Herzberg Benjamin O
Abstract excerpt
BACKGROUND: 20% of patients with cancer are estimated to be ineligible for phase III trials because of restrictive eligibility criteria. Ineligibility rates for earlier phase trials are even greater. In response, several groups, including the US Food and Drug Administration, have advocated for more inclusive study designs. We examined Kirsten rat sarcoma virus (KRAS) G12C inhibitor trials to determine if...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.